Caregen , a biotechnology company, is accelerating its advance into the global market. Recently, Caregen officially registered its cosmetic products and raw materials with India’s Central Drugs Standard Control Organization (CDSCO), further strengthening its position in the global cosmeceutical market.
Caregen is a company that competes not with simple brand marketing but with the technology to develop unique raw materials and manufacture and produce them directly. Unlike general cosmetics companies that attack the market with brand and marketing strategies, Caregen is differentiated in that it develops and produces patented high-functional raw materials based on core technologies and supplies them directly to cosmetics and pharmaceutical companies around the world.
In the midst of the global expansion of K-Beauty, Caregen's peptide-based functional raw materials are comprised of ingredients whose effectiveness has been proven through scientific research and verification, and are not just a simple trend but are acting as sustainable competitiveness.
The Indian cosmetics market has recently been growing remarkably due to changes in consumer preferences, increased purchasing power, and increasing interest in personal grooming. The Indian Beauty & Personal Care market size in 2022 was approximately USD 26.3 billion and is expected to grow at a CAGR of 6.45% from 2023 to 2028, reaching USD 38 billion by 2028.
Caregen develops and produces raw materials and products based on its own peptide technology, and supplies high-concentration functional products at competitive prices. Indian consumers are highly interested in functional cosmetics containing active ingredients, so Caregen’s innovative peptide raw materials and products are expected to have a strong response in the local cosmeceutical market.
According to the data released by the Korean Intellectual Property Office on the 17th, Caregen has proven its unrivaled technological prowess by holding 115 patents for hair loss-related substances, ranking first in the world. Caregen's hair care solutions are characterized by their various functions, such as hair growth promotion and scalp health improvement, beyond simple hair loss prevention. Caregen continues innovative research and development by applying for and registering over 750 synthetic peptide substances that can be used in the entire biomedical field, such as pharmaceutical raw materials for ocular and oral health, and clinical physiological applications, as well as hair loss-related substances.
Through this CDSCO registration, Caregen has successfully entered the Indian market with various high-functional raw materials and products, including ▲PTx (a peptide with the function of topical botulinum toxin that improves skin anti-aging, including wrinkles, and reduces pores and pain, as well as a trouble care product), ▲iDR (an innovative product that repairs damaged hair within 5 minutes and has effects that last for 7 days with a single use), and ▲Pelobaum (a topical version of hair filler that prevents hair loss and promotes hair growth and improvement).
Caregen CEO Jeong Yong-ji said, “With this Indian cosmetics registration as an opportunity, we will export cosmetic raw materials and products through AKUMS, India’s largest CDMO (Contract Development and Manufacturing Organization),” and “Through cooperation with AKUMS, we will expand strategic partnerships with global brands and lead the functional cosmetics market.” He continued, “The products supplied this time will be distributed and sold through about 30 major companies, including Sun Pharmaceutical and Cipla, India’s largest pharmaceutical companies,” and “Indian companies, in particular, are mostly corporations that close their books in March, and their 2025 fiscal year will begin in earnest in April. In the new fiscal year, we expect cooperation centered on Caregen products to expand further, becoming a key driving force for future sales growth.”
Caregen is expected to complete registration of not only its cosmetics but also its dermal filler medical device products such as Dr. CYJ hair filler, PTx Dimono, and Levofil around May. In addition, it is in the process of registering ProGsterol, Myoki, and Korglutide as medical foods and plans to start supplying products in earnest within the year. Through this, it is expected to further strengthen its position in the global bio-healthcare market.
Caregen plans to continue to engage in research and development (R&D) and new market development to expand its influence in the global market in the future. With this registration as an opportunity, the company plans to lead the global functional cosmetics and pharmaceutical market as well as the Indian market by leveraging its bio-healthcare technology.
- See more related articles
You must be logged in to post a comment.